Comparative Pharmacology
Head-to-head clinical analysis: CHLORZOXAZONE versus STRIFON FORTE DSC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORZOXAZONE versus STRIFON FORTE DSC.
CHLORZOXAZONE vs STRIFON FORTE DSC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Caffeine is a central nervous system stimulant that acts as an antagonist at adenosine receptors (A1 and A2A subtypes), thereby reducing the inhibitory effects of adenosine. Dihydroergotamine is an ergot alkaloid with partial agonist activity at serotonin 5-HT1B/1D receptors, leading to vasoconstriction of cranial blood vessels. Thioridazine is a typical antipsychotic with high affinity for dopamine D2 receptors and moderate affinity for serotonin 5-HT2A, alpha1-adrenergic, and histamine H1 receptors.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Chlorzoxazone 500 mg to 750 mg orally three to four times daily.
None Documented
None Documented
Clinical Note
moderateChlorzoxazone + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Fluticasone propionate."
Clinical Note
moderateChlorzoxazone + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Tenofovir disoproxil
"The metabolism of Tenofovir disoproxil can be decreased when combined with Chlorzoxazone."
Clinical Note
moderateChlorzoxazone + Sulfisoxazole
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
10-12 hours in healthy adults; prolonged to 18-24 hours in hepatic impairment or elderly
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Renal excretion of unchanged drug (70-90%) and glucuronide conjugates; biliary/fecal elimination accounts for <10%
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant
"The metabolism of Sulfisoxazole can be decreased when combined with Chlorzoxazone."